Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Terminated NCT00901160

Thromboelastography (TEG®) and Platelet Function in Patients on Anti-platelet Agents

Conditions: Blood Clotting

Sex: All

Ages: 40 Years – 85 Years

Healthy volunteers: No

Enrollment: 200

Sponsor: McMaster University

Location: Hamilton Health Sciences Hamilton Ontario

Summary

Can a post-operative analysis using a simple blood test (Thromboelastography(TEG®)) and Platelet Mapping Assay (PMA™) be able to detect the occurence of clotting or bleeding complications in patients on blood thinning (anti-platelet) agents?

Eligibility Criteria

Inclusion Criteria: * patients on aspirin and/or clopidogrel for at least 10 days, having non-ambulatory, non-cardiac, elective surgery Exclusion Criteria: * anemia (Hb \< 100) or thrombocytopenia (platelet count \< 80), having any known clotting abnormalities * family history of clotting abnormalities * concurrently on NSAIDs, warfarin therapy or other treatments affecting platelet function * renal impairment (Cr \> 110 mg for females or Cr \> 125 mg) or INR \> 1.2

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT00901160). StuddyBuddy aggregates publicly available trial information.